ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO834

Histologic vs Clinical Remission in Proliferative Lupus Nephritis at 6 Months - An Experience from a State Run Tertiary Care Centre in Southern India

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Author

  • L, Umesh, Institute of nephrourology, Bangalore, India
Background

Aim and objective of this study is to describe the renal histology of the second biopsy and correlate histopathological remission with clinical remission at 6 months.

Methods

The study conducted in Department of Nephrology, Institute of Nephro-Urology, Victoria Hospital Campus Bangalore, India between Oct 2015 and Nov 2017. A total of 50 consecutive patients with biopsy proven Proliferative Lupus Nephritis were included in the study. Clinical response was defined as complete (CRR), partial (PRR) or non-response (NRR) according to recent definitions. Histological response (HR) was defined as Class I, II or III/IV-C on repeat biopsies.

Results

1/3 rd cases who were achieved complete remission clinically failed to achieve histological remission. Out of 19 patients 12(63%) had transformation to favorable class in CRR group. Out of 19 patients 12(63%) in PPR group and out of 12 patients 8(66%) in NRR group had unfavorable class at 6 months. Though Chronicity Index increased in all clinical subgroups, non responders had statistically significant increased CI.

Conclusion

The protocol renal biopsies performed at six months demonstrated an increase in chronicity, especially within the same histological class. 1/3rd patients with complete remission group had active lesions at the end of induction treatment, questioning the current induction therapy of 6 months which may not be sufficient. More RCTs are needed to test whether repeated biopsies should be considered as a part of the evaluation of treatment response in LN.